Clinical Trial: The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07671924) titled 'The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)' on June 22.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Nalbuphine ER Extended-release tablets for the treatment of participants with RCC.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Refractory Chronic Cough

Intervention: DRUG: NAL ER

Oral tablets

DRUG: Placebo

Oral tablets

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Trevi Therapeutics

Disclaimer: Curated by HT Syndication....